

<h3>Bibliografía</h3>

    <ol>
        <li>Dicke C, Langer F. Pathophysiology of Trousseau’s syndrome. Hämostaseologie 2015;35:52-9.</li>
        <li>Langer F, Bokemeyer C. Crosstalk between cancer and haemostasis. Hämostaseologie 2012;32:95-104.</li>
        <li>Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-22.</li>
        <li>Buller HR, van Doormaal FF, Van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemosta 2007;5(Suppl 1):246-54.</li>
        <li>Van Es N, Bleker SM, Wilts IT, Porreca E, Di Nisio M. Prevention and treatment of venous thromboembolism in patients with cancer: Focus on drug therapy. Drugs 2016;76(3):331-41.</li>
        <li>Akl EA, Terrenato I, Barba M, Sperati F, Muti P, Schünemann HJ. Extended perioperative thromboprophylaxis in patients with cancer: a systematic review. Thromb Haemost 2008; 100:1176-80.</li>
        <li>Di Nisio M, Porreca E, Otten H-M, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;1;12.</li>
        <li>Kamphuisen PW, Beyer-Westendorf J. Bleeding complications during anticoagulant treatment in patients with cancer.  Thromb Res 2014;133(Suppl 2):49-55.</li>
        <li>Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study. J Thromb Haemost 2015;13(6):1028-35.</li>
        <li>Liebman HA. Thrombocytopenia in cancer patients. Thromb Rese 2014;133(Suppl 2):63-9.</li>
        <li>Levi M. Management of cancer-associated disseminated intravascular coagulation. Thromb Res 2016;140(Suppl 1):66-70</li>
    </ol>